|
Price: $4.0099
$0.05
1.260%
|
Day's High:
| $4.39
| Week Perf:
| -12.45 %
|
Day's Low: |
$ 3.87 |
30 Day Perf: |
-27.49 % |
Volume (M): |
1,071 |
52 Wk High: |
$ 12.69 |
Volume (M$): |
$ 4,296 |
52 Wk Avg: |
$6.41 |
Open: |
$4.05 |
52 Wk Low: |
$1.54 |
|
|
Market Capitalization (Millions $) |
197 |
Shares
Outstanding (Millions) |
49 |
Employees |
- |
Revenues (TTM) (Millions $) |
100 |
Net Income (TTM) (Millions $) |
-218 |
Cash Flow (TTM) (Millions $) |
4 |
Capital Exp. (TTM) (Millions $) |
14 |
2seventy Bio Inc
2seventy Bio Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of various diseases. The company employs advanced genetic and protein engineering techniques to create innovative drug candidates. Their research and development efforts are primarily focused on oncology and rare diseases. 2seventy Bio Inc aims to provide targeted and effective treatments that address critical unmet medical needs.
Company Address: 60 Binney Street Cambridge 2142 MA
Company Phone Number: 675-7270 Stock Exchange / Ticker: NASDAQ TSVT
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
2seventy Bio Inc
In the fast-paced world of biotechnology and pharmaceuticals, companies are constantly striving to revolutionize the field of healthcare. One such company making waves is 2seventy Bio Inc (NASDAQ: TSVT), a pioneering immuno-oncology cell therapy company based in Cambridge, Massachusetts. In recent news, the company has reiterated its commitment to maximizing shareholder value, signaling a bold move that sets the stage for future success. Recognizing the importance of shareholder value, the Board of Directors at 2seventy Bio Inc initiated a comprehensive process last month to explore all available avenues in order to maximize value. This proactive approach showcases the company's determination to propel itself to new heights and unlock its full potential. With this ongoing process already well underway, the team at 2seventy Bio Inc is diligently working towards ensuring that their groundbreaking therapies reach those in need as quickly as possible.
|
Business Update
Published Wed, Dec 6 2023 7:00 PM UTC
2seventy bio Reiterates Commitment to Maximizing Shareholder Value CAMBRIDGE, Mass. - In a bold move that sets the stage for future success, 2seventy bio, Inc. (NASDAQ: TSVT), a pioneering immuno-oncology cell therapy company, has reaffirmed its dedication to maximizing shareholder value. With their unwavering commitment, 2seventy is poised to revolutionize the field of ...
|
2seventy Bio Inc
The stock market can be a rollercoaster ride for investors, with ups and downs that can sometimes leave even the most experienced traders feeling a bit queasy. However, amid the turbulence, there are still plenty of opportunities for those who keep a keen eye on the numbers. In the third quarter of 2023, TSVT faced a loss of $-1.40 per share. While this may not seem like cause for celebration, it is actually an improvement from their loss of $-1.76 per share a year ago. Furthermore, compared to the previous financial reporting period where the shortfall was $-0.83 per share, TSVT has made significant progress. This indicates that the company is actively working to improve their financial performance, which is a positive sign for investors.
|
2seventy Bio Inc
2seventy Bio Inc: A Closer Look at the Financials 2seventy Bio Inc, a biotech company specializing in advanced medical treatments, recently released its financial report for the period closing June 30, 2023. The report highlights significant improvements in key financial indicators, such as earnings per share (EPS) and revenue growth. Additionally, the company's accounts receivable and stock performance provide further insights into its financial standing. Let's delve deeper into these findings and gain a better understanding of 2seventy Bio Inc's financial health. Earnings Per Share (EPS) and Net Deficit One of the most promising aspects of 2seventy Bio Inc's financial report is the reduction in its loss per share. In the financial span ending June 30, 2023, the company decreased its loss per share to $-0.83, a significant improvement from $-2.02 reported a year ago. Furthermore, EPS improved from $-1.08 in the preceding reporting period. This development suggests that 2seventy Bio Inc's performance has been steadily improving, indicating a positive trend for the company's profitability.
|
2seventy Bio Inc
2seventy Bio Inc: A Growing Company with Positive Financial Results 2seventy Bio Inc is a leading healthcare company that focuses on research and development of innovative therapies for rare diseases. The company is based in the United States and was founded in 2016. Since then, it has made significant progress in advancing the medical field with its unique approach to drug discovery and development. The company recently announced excellent financial results for the first quarter of 2023. The revenue for the quarter increased by a staggering 393.783% year on year to $41.62 million. However, the company still reported a net loss of $-1.08 per share, which was an improvement from the previous fiscal year's loss of $0.00. The revenue fell by -25.911% from $56.18 million in the preceding reporting season.
|
Per Share |
Current |
Earnings (TTM) |
-4.2 $ |
Revenues (TTM) |
2.04 $
|
Cash Flow (TTM) |
0.09 $ |
Cash |
1.52 $
|
Book Value |
5.19 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-4.2 $
|
Revenues (TTM) |
2.04 $ |
Cash Flow (TTM) |
0.09 $ |
Cash |
1.52 $
|
Book Value |
5.19 $ |
Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com